Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–8 of 8 results
Advanced filters: Author: Itamar Raz Clear advanced filters

  • The latest findings from the EMPA-REG OUTCOME trial show a 34% reduction in hospitalization for heart failure or cardiovascular death in patients receiving empagliflozin, a sodium/glucose cotransporter 2 (SGLT2) inhibitor, compared with placebo. These outstanding results call for discussion of the clinical implications, and in-depth studies of the mechanisms of action of SGLT2 inhibitors.

    • Itamar Raz
    • Avivit Cahn
    News & Views
    Nature Reviews Cardiology
    Volume: 13, P: 185-186

  • Amyloid fibrils assembled by an alternating lysine/phenylalanine peptide exhibit remarkable catalytic properties for β-lactam antibiotic hydrolysis. Specifically, the fibrils adopt coiled-coil structure underscoring an allosteric catalytic mechanism.

    • Sisira Mambram Kunnath
    • Elad Arad
    • Raz Jelinek
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-14

  • In an analysis of five large randomized clinical trials testing established therapies for cardiovascular disease, individuals with clonal hematopoiesis had an increased risk for first but not recurrent myocardial infarction as compared to individuals without clonal hematopoiesis, and did not show increased benefit from any of the therapies tested.

    • Nicholas A. Marston
    • James P. Pirruccello
    • Christian T. Ruff
    Research
    Nature Medicine
    Volume: 30, P: 2641-2647

  • Lowering blood pressure to normal levels, below those currently recommended, does not reduce the risk of cardiovascular disease events in patients with type 2 diabetes mellitus. Nor does treating dyslipidemia with fibrate and statin combination therapy reduce the risk of cardiovascular disease events more than treatment with statin alone.

    • Mariela Glandt
    • Itamar Raz
    News & Views
    Nature Reviews Endocrinology
    Volume: 6, P: 483-484

  • A meta-analysis of individual-level patient data from 66 clinical studies supports the utility of glomerular filtration rate as a surrogate endpoint in clinical trials for chronic kidney disease, with potential to enable detection of events earlier in the disease course.

    • Lesley A. Inker
    • Willem Collier
    • Mauro Saddelli
    Research
    Nature Medicine
    Volume: 29, P: 1867-1876

  • Type 2 diabetes mellitus is a chronic metabolic disorder associated with hyperglycaemia caused by impaired insulin secretion and insulin resistance. In this Primer, DeFronzo et al. discuss the pathophysiology, diagnosis, and current and future treatment strategies.

    • Ralph A. DeFronzo
    • Ele Ferrannini
    • Ram Weiss
    Reviews
    Nature Reviews Disease Primers
    Volume: 1, P: 1-22